Skip to main content
Contact Us
Subscribe
E-Edition
77°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Archives
Best of 2025
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Lexaria Bioscience Corp. - Warrant
(NQ:
LEXXW
)
0.1701
-0.0102 (-5.66%)
Streaming Delayed Price
Updated: 1:17 PM EDT, May 19, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Lexaria Bioscience Corp. - Warrant
< Previous
1
2
3
4
5
6
7
8
Next >
Lexaria to Receive $4.7 Million Gross Proceeds in Warrant Exercise and Issuance
April 30, 2024
Via
ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Receives Approval to Commence Human Pilot Study Evaluating GLP-1, DehydraTECH
April 16, 2024
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria Receives Ethics Review Board Approval to Begin New GLP-1 Study
April 16, 2024
Via
ACCESSWIRE
Lexaria Awarded New Patents
April 02, 2024
Via
ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Names Experienced Corporate Finance Exec as New CFO
March 14, 2024
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria Unveils Extensive Planned 2024 GLP-1 Study Program
January 16, 2024
Via
ACCESSWIRE
Lexaria Appoints Nelson Cabatuan as Chief Financial Officer
March 14, 2024
Via
ACCESSWIRE
Lexaria Awards Contract For Next GLP-1 Human Pilot Study
March 07, 2024
Via
ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) to Commence Diabetes and Weight Loss Animal Study
March 05, 2024
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria to Begin Diabetes and Weight Loss Animal Study WEIGHT-A24-1
March 05, 2024
Via
ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Weight-Loss Results in Animal Study, Begins Eight-Week Follow-Up Study
March 04, 2024
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
7% Weight Loss in Animals Supports Lexaria’s Next 8-week Animal Study
March 04, 2024
Via
ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Cleared to Commence HYPER-H23-1 Clinical Trial
March 01, 2024
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
Lexaria Announces FDA Clearance for its Planned U.S. Phase 1b Hypertension Clinical Trial
March 01, 2024
Via
ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Closing of $3.6M Registered Direct Offering
February 20, 2024
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria Announces Closing of $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
February 16, 2024
Via
ACCESSWIRE
Lexaria Announces $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
February 15, 2024
Via
ACCESSWIRE
Lexaria's Submits Investigational New Drug Application
January 30, 2024
Via
ACCESSWIRE
Lexaria Releases Annual Letter from the CEO
January 24, 2024
Via
ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Extensive GLP-1 Study Program
January 16, 2024
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria's Investigational New Drug Application Filing Update
December 07, 2023
Via
ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Proprietary Tech Lowers Blood Glucose More Effectively than Branded GLP-1 drug Semaglutide Alone, Study Shows
November 28, 2023
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria's Technology Lowers Blood Glucose More Effectively than Rybelsus(R)-Branded GLP-1 drug Semaglutide Alone in Human Pilot Study
November 28, 2023
Via
ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Shown to Improve Oral Performance of GLP-1 Drug in Human Pilot Study
November 27, 2023
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria Enters New Global Exclusive Collaboration and License Agreement with SulfoSyn
October 13, 2023
Via
ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Portfolio Expansion to 37 Granted Patents
October 12, 2023
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria Granted Two New Patents in Canada
October 12, 2023
Via
ACCESSWIRE
Lexaria Announces Pricing of $1.6 Million Registered Direct Offering
September 29, 2023
Via
ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces New Studies to Examine DehydraTECH(TM)-Powered GLP-1 Drugs
September 21, 2023
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria to Evaluate Impact of DehydraTECH on Oral Performance of GLP-1 drugs used in products such as Ozempic, Wegovy and Rybelsus, Alone or Together with DehydraTECH-CBD
September 21, 2023
Via
ACCESSWIRE
< Previous
1
2
3
4
5
6
7
8
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.
